The “Clinton v Trump,” “Democrat v Republican,” and FLOTUS v FLOTUS continue to riddle the news wires this week, just days before the 2016 Presidential race will come to an end. Speculation continues to rise amidst buzz of rate hikes and jobs numbers. But while strategists and economists clash over the impact that the election will have on U.S. markets, there are several stocks that have maintained steady uptrends, weathered volatility, and have even managed to inch toward new session highs. These include American Cannabis Company, Inc. (AMMJ), EXOLIFESTYLE INC (EXOL), Amyris, Inc. (AMRS), and InspireMD, Inc. (NSPR).
A quick glance at a 4 week chart and its easy to see that American Cannabis Company (AMMJ) has managed to captivate considerable interest. On Tuesday the stock soared to highs of $2.00 during the first half of the trading session. This company has recently gotten caught in the frenzy that many companies within the marijuana sector have seen ahead of the election. Speculation has been abuzz as many stocks in the space rise. Over the last few weeks shares of American Cannabis have increased from $0.20 to Tuesday’s highs, which also marked new 2-year highs for the stock.
ExoLifestyle Inc. (EXOL) has also seen its fair share of positive movement having jumped over 160% since Mid October. The company has recently announced that Rogue Fitness HQ will be one of the company’s major USA Distributors for their brand of knee wraps and knee sleeves. In a statement, President Randy Romano said, “We currently have received several purchase orders from Rogue Fitness and as a result of increasing our inventory recently we are now able to fulfill these purchase orders. Rogue Fitness is one of the largest wholesalers and distributors in the business and we are extremely excited to have them on board as a distributor." For more info on EXOlifestyle, Inc. (EXOL) visit http://bit.ly/2eTypx2
Having been on the rise since mid-September, Amyris, Inc. (AMRS) has managed to climb as high as $1.21 during the month of October. After consolidating to as low as $0.96 last Friday, shares have rebounded by as much as 12.5% following November’s high of $1.08. The company announced on Monday that management will be presenting its detailed update on recently announced collaborations as well as the forward outlook for the company via a scheduled investor day in New York. The company focuses on innovative bioscience solutions to convert plant sugars into hydrocarbon and produce special ingredients & consumer products.
InspireMD (NSPR) has been one of the most active stock on Tuesday having traded nearly 10 times its three month average. The company announced this morning that 12-month follow up data from PARADIGM-101 of the CGuard Embolic Prevention System were presented at the Transcatheter Cardiovascular Therapeutics 2016 scientific symposium this week. The company revealed that there was zero device related adverse events at 12 months and showed that vessel narrowing was reduced. The markets reactions seems to have been positive as the share price rose to highs of $4.39 and marked an intra day move of 167.7%.
Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are subject to change without notice.We assume no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.